Price
No data yet.
Social Signal Score
Analyst Ratings
26 analystsRevenue
$321.19M+145.97%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Kim Kelderman
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 3,000
- Beta
- 1.27
- Country
- US
- Piotroski score
- 8 / 9 (Strong)
- Altman Z-score
- 15.89
Financials
Revenue
$321.19M+146.0%Net Income
$54.61M+235.4%EBITDA
$91.90M+85.2%Free Cash Flow
$86.94M+268.2%EPS (diluted)
$0.36+227.3%Shares Outstanding (diluted)
157.01M+4.7%Operating Expenses
$137.12MCash & Debt
$264.71MReturn of Capital
$54.13MRevenue by Segment (annual)
$1.12BDividend per Share
$0.08Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2026 | $1.22B | $181.86M | $1.17 |
| 2025 | $1.22B | $73.40M | $0.47 |
| 2024 | $1.16B | $168.10M | $1.07 |
| 2023 | $1.14B | $285.26M | $1.81 |
| 2022 | $1.11B | $272.05M | $1.73 |
| 2021 | $931.03M | $140.41M | $0.91 |
| 2020 | $738.69M | $229.30M | $1.50 |
| 2019 | $714.01M | $96.07M | $0.64 |
| 2018 | $642.99M | $125.35M | $0.84 |
| 2017 | $563.00M | $77.29M | $0.52 |
| 2016 | $499.02M | $104.48M | $0.70 |
| 2015 | $452.25M | $107.73M | $0.73 |
| 2014 | $357.76M | $110.95M | $0.75 |
| 2013 | $310.57M | $112.56M | $0.76 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from TECH's reported EPS growth of 3.4% a year over 13 years.
- EPS in 5 years
- $1.38
- Implied price
- $24.81
- Return from $72.40
- -19.3% a year
To earn 15.0% a year on these assumptions you'd need to buy at $12.33 — -83.0% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 12 | 15 | 18 | 21 | 24 |
|---|---|---|---|---|---|
| -6.6% | -32.8% | -29.7% | -27.1% | -24.8% | -22.8% |
| -1.6% | -29.2% | -25.9% | -23.2% | -20.8% | -18.6% |
| 3.4% | -25.6% | -22.2% | -19.3% | -16.8% | -14.5% |
| 8.4% | -22.0% | -18.4% | -15.4% | -12.7% | -10.4% |
| 13.4% | -18.4% | -14.6% | -11.5% | -8.7% | -6.2% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
50-50.00%Social Signal Score
Mentions (25)
- 4chan /biz/biz·2d ago·Neutral
EXPECTATIONS NEVER CHANGE LEVERAGE NEVER CHANGES THE TECH DOESN'T MATTER THINK ABOUT IT
View source ↗ - 4chan /biz/biz·6d ago·Neutral
F****** BREAK TECH ALREADY 5.3% 10 YEAR ORACLE BONDS YIELD 9% ANTHROPIC OPENAI BURN 700B A YEAR CORRELATE TO 1 NOW
View source ↗ - Newsprnewswire.com·6d ago·Neutral
INTURAI PROVIDES DEFENCE TECH COMPETITION RESULTS AND COMPANY UPDATE (CSE: URAI / OTC: URAIF / FSE: 3QG0) investor@inturai.com DomeCommand, the drone command-and-control platform the Company recently acquired, won first and third place in the two-day team integration category at the Singapore Defense Tech Hackathon 2026, in entries collaborating with partner teams. In the first-place entry, Team Echelon connected its acoustic localisation system and Team Aegis connected its interceptor drone to …
View source ↗ - News (Marketaux)gurufocus.com·12d ago·Positive
Bio-Techne (TECH) Shareholders Approve $Merger Agreement With Merck KGaA Bio-Techne Corpora[+325 characters]
View source ↗ - Newsprnewswire.com·13d ago·Neutral
Bio-Techne Shareholders Approve Acquisition by Merck KGaA, Darmstadt, Germany MINNEAPOLIS, Sept. 23, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) ("Bio-Techne"), a global provider of life science tools, reagents and diagnostic products, announced that Bio-Techne shareholders voted to approve and adopt the definitive agreement under which Merck KGaA, Darmstadt, Germany proposes to acquire Bio-Techne (the "Merger Agreement") at a Special Meeting of Shareholders held today.
View source ↗ - Newsprnewswire.com·14d ago·Negative
…, training and innovation within Europe's life sciences community MINNEAPOLIS and DÜSSELDORF, Germany, Sept. 22, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents and diagnostic products, today announced the opening of its new Customer Experience Center in Düsseldorf, Germany, a flagship facility designed to bring European customers closer to Bio-Techne's latest innovations and scientific expertise.
View source ↗ - Newszacks.com·24d ago·Neutral
Why Is Techne (TECH) Down 0.1% Since Last Earnings Report? Techne (TECH) reported earnings 30 days ago. What's next for the stock?
View source ↗ - Newsseekingalpha.com·25d ago·Negative
CMB.TECH: Updates From Our Top Shipping Pick Of 2026 CMB.TECH delivered a 134% return in under a year, driven by a strategic dry bulk focus and strong tanker markets. I recently interviewed the CEO and CFO to get updates on the dry bulk industry and company-specific strategy. CMBT maintains a flexible, discretionary dividend policy, targeting 50–60% of net income over time while preserving capital for counter-cyclical opportunities.
View source ↗ - Newsglobenewswire.com·28d ago·Neutral
PRESS RELEASE: CMB.TECH announces special general meeting on 8 October 2026 ANTWERP, Belgium, 8 September 2026, 08:00 a.m. CET – CMB.TECH NV (NYSE: CMBT & Euronext: CMBT) (“CMB.TECH” or the “Company”) (NYSE: CMBT, Euronext Brussels: CMBT en Euronext Oslo Børs: CMBTO) invites its shareholders to participate in the Special General Meeting that will be held on Thursday 8 October 2026.
View source ↗ - 4chan /biz/biz·29d ago·Neutral
TECH conversation Can we please have a discussion on the TECHNOLOGICAL differences between these two? Some points to start off with: -ZEC lacks fungibility and shielded pools operate more like coin mixers than a genuine privacy function due to optional shielding -Neither ZEC nor XMR are quantum-proof, but with FCMP++, XMR will become quantum-resistant, and have parity with, or surpass ZEC in terms of anonymity set size -Current XMR ring size of 16 is entirely insufficient and may be vulnerabl…
View source ↗ - Newsprnewswire.com·35d ago·Neutral
…now comes from renewable sources First comprehensive Scope 3 emissions inventory completed MINNEAPOLIS, Sept. 1, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents and diagnostic products, today announced significant progress toward its climate and sustainability objectives, including validation of its greenhouse gas reduction targets by the Science Based Targets initiative (SBTi) and substantial reductions in operational emissions durin…
View source ↗ - Newsseekingalpha.com·39d ago·Neutral
CMB.TECH: Q2 Was Strong, But Valuation Looks Full (Downgrade) CMB.TECH (CMBT) shows improved earnings quality as core shipping EBITDA rises despite reduced ship sales. Q2 revenue and EBITDA surged, but backlog growth stalled, raising concerns about long-term contract momentum. A strategic ammonia-powered vessel agreement with Fortescue signals tangible progress in clean fuel initiatives.
View source ↗ - News (RSS)hellenicshipping·39d ago·Neutral
CMB.TECH Expects Continued Strength In Seaborne Iron Ore Trade CMB.TECH NV reported its unaudited financial results today for the second quarter ended 30 June 2026. HIGHLIGHTS Financial highlights: • Profit for the period of USD 364.4 million in Q2 2026. • EBITDA for the same period was USD 552.8 million. • CMB.TECH’s contract backlog stable at USD 3.26 billion with the addition of 2 ...
View source ↗ - News (RSS)seekingalpha·39d ago·Neutral
CMB.TECH NV 2026 Q2 - Results - Earnings Call Presentation
View source ↗ - Newsseekingalpha.com·39d ago·Positive
CMB.TECH NV (CMBT) Q2 2026 Earnings Call Transcript CMB.TECH NV (CMBT) Q2 2026 Earnings Call Transcript
View source ↗ - Newsmarketbeat.com·39d ago·Positive
CMB.TECH Q2 Earnings Call Highlights CMB.TECH NYSE: CMBT reported second-quarter 2026 net profit of $364.4 million, supported by revenue of more than $700 million and $127 million in gains from vessel sales, as shipping markets remained strong across several of the company's operating segments.
View source ↗ - Newsglobenewswire.com·40d ago·Neutral
CMB.TECH ANNOUNCES Q2 2026 RESULTS ANTWERP, Belgium, 27 August 2026 – CMB.TECH NV (“CMBT”, “CMB.TECH” or “the company”) (NYSE: CMBT, Euronext Brussels: CMBT and Euronext Oslo Børs: CMBTO) reported its unaudited financial results today for the second quarter ended 30 June 2026.
View source ↗ - Newsbusinesswire.com·45d ago·Neutral
TECH Stock Alert: Halper Sadeh LLC is Investigating Whether Bio-Techne Corporation is Obtaining a Fair Price for its Shareholders NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Bio-Techne Corporation (NASDAQ: TECH) to Merck KGaA for $73.00 per share in cash. Halper Sadeh encourages Bio-Techne shareholders to click here to learn more about their rights and options or contact Daniel Sadeh or Zachary Halper free of charge at (212) 763-0060 or …
View source ↗ - 4chan /biz/biz·45d ago·Negative
I tweaked my portfolio again. I've been tweaking it for over a year now. Here it is. Feel free to copy it. SLEEVE 1: TECH, GROWTH AND ROTATION CORE (29.0%) CHAT 10.0% IGM 6.0% SGRT 5.0% SPYG 5.0% QQQA 3.0% SLEEVE 2: US EQUITY CORE, VALUE AND MOMENTUM (27.0%) FDL 10.0% JQUA 7.0% DIVB 5.0% FMTM 5.0% SLEEVE 3: INTERNATIONAL VALUE (13.0%) FNDF 10.0% DXJ 3.0% SLEEVE 4: REAL ASSETS (12.5%) YGLD 6.0% MADE 3.0% ERX 1.5% GRID 1.0% MXI 1.0% SLEEVE 5: LIQUID AND TREND (18.5%) KMLM 5.5% CTA 5.0% DBMF 4.5% …
View source ↗ - Newszacks.com·53d ago·Positive
TECH Q4 Earnings Meet Estimates, Revenues Surpass, Stock Rises Bio-Techne's Q4 revenues beat estimates as Diagnostics and Spatial Biology deliver strong organic growth, while its Merck deal remains in focus.
View source ↗ - Newsprnewswire.com·54d ago·Neutral
Bio-Techne Corrects Dividend Announcement MINNEAPOLIS, Aug. 13, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) is issuing a correction to its dividend announcement released yesterday. The initial version incorrectly stated the shareholder of record date as August 17, 2026.
View source ↗ - Newsglobenewswire.com·54d ago·Neutral
CMB.TECH ANNOUNCES Q2 2026 RESULTS ON 27/08/2026 ANTWERP, Belgium, 13 August 2026 – CMB.TECH NV (NYSE: CMBT, Euronext Brussels: CMBT and Euronext Oslo Børs: CMBTO) (“CMBT”, “CMB.TECH” or “the Company”) will release its second quarter 2026 earnings prior to market opening on Thursday 27 August 2026 and will host a conference call at 8 a.m. EST / 2 p.m. CET to discuss the results for the quarter. The half year report will be published on 3 September 2026.
View source ↗ - Newszacks.com·55d ago·Neutral
Techne (TECH) Q4 Earnings Meet Estimates Techne (TECH) came out with quarterly earnings of $0.52 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $0.53 per share a year ago.
View source ↗ - Newsprnewswire.com·55d ago·Neutral
Bio-Techne Declares Dividend MINNEAPOLIS, Aug. 12, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended June 30, 2026. The quarterly dividend will be payable August 28, 2026, to all common shareholders of record on August 17, 2026.
View source ↗ - Newsprnewswire.com·55d ago·Neutral
Bio-Techne Releases Fourth Quarter Fiscal 2026 Results MINNEAPOLIS, Aug. 12, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the fourth quarter ending June 30, 2026. Fourth Quarter FY2026 Highlights Fourth quarter organic revenue increased by 3% (1% reported) to $321.2 million.
View source ↗
Earnings
Wed, Nov 4(in 4 weeks)
Consensus estimate $0.44 per share
Typical surprise +6.0% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 12$0.52 vs $0.52beat
- Wed, May 6$0.53 vs $0.55miss
- Wed, Feb 4$0.46 vs $0.43beat
- Wed, Nov 5$0.42 vs $0.42miss
- Wed, Aug 6$0.53 vs $0.50beat
- Wed, May 7$0.56 vs $0.51beat
Estimates and results for TECH via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by TECH officers and directors.
- Bought
- —
- Sold
- $320k
0 trades
1 trade
- Herr Amy E.sold
99 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- April McClain Delaneyhouse · MD06 · disclosed May 7, 2026 (29d later)Sell$1,001 - $15,000
- April McClain Delaneyhouse · MD06 · disclosed Apr 8, 2026 (13d later)Sell$1,001 - $15,000
- April McClain Delaneyhouse · MD06 · disclosed Mar 11, 2026 (15d later)Sell$1,001 - $15,000
- April McClain Delaneyhouse · MD06 · disclosed Feb 3, 2026 (6d later)Sell$1,001 - $15,000
- April McClain Delaneyhouse · MD06 · disclosed Jan 6, 2026 (32d later)Buy$1,001 - $15,000
- April McClain Delaneyhouse · MD06 · disclosed Jan 6, 2026 (35d later)Buy$1,001 - $15,000
- April McClain Delaneyhouse · MD06 · disclosed Nov 5, 2025 (14d later)Buy$1,001 - $15,000
- April McClain Delaneyhouse · MD06 · disclosed Sep 3, 2025 (33d later)Sell$1,001 - $15,000
- April McClain Delaneyhouse · MD06 · disclosed Jul 3, 2025 (38d later)Sell$1,001 - $15,000
- Julie Johnsonhouse · TX32 · disclosed May 15, 2025 (44d later)Sell$1,001 - $15,000
- Robert P. Bresnahanhouse · PA08 · disclosed May 8, 2025 (30d later)Sell$1,001 - $15,000
- April McClain Delaneyhouse · MD06 · disclosed May 2, 2025 (23d later)Buy$1,001 - $15,000
- April McClain Delaneyhouse · MD06 · disclosed May 2, 2025 (3d later)Buy$1,001 - $15,000
- Robert P. Bresnahanhouse · PA08 · disclosed Mar 28, 2025 (31d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Dec 6, 2023 (33d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Nov 8, 2023 (37d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Jul 11, 2023 (15d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Jun 12, 2023 (20d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed May 8, 2023 (28d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Apr 7, 2023 (24d later)Buy$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.